A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19
Yeon-Sook Kim, Seng-Ho Jeon, Junghee Kim, Jong Hoon Koh, Seung Won Ra, Ji Won Kim, Yeonjae Kim, Choon Kwan Kim, Yun Chul Shin, Beo Deul Kang, Seung Ji Kang, Chul Hee Park, Boyoung Lee, Ji Yeon Lee, Chung Hoon Lee, Jae-Phil Choi, Jin Yong Kim, Shi Nae Yu, Kyong Ran Peck, Sung-Han Kim, Jung Yeon Heo, Hyun Ah Kim, Hyun-Jin Park, Jongwon Choi, Jumi Han, Joohyun Kim, Hyoung Jun Kim, Se Hee Han, Aeri Yoon, Mihee Park, Sujung Park, Yukyung Kim, Minji Jung, Myoung-Don Oh
Antimicrobial Agents and Chemotherapy, doi:10.1128/aac.00452-22
Although several antiviral agents have become available for coronavirus disease 2019 (COVID-19) treatment, oral drugs are still limited. Camostat mesylate, an orally bioavailable serine protease inhibitor, has been used to treat chronic pancreatitis in South Korea, and it has an in vitro inhibitory potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study was a doubleblind, randomized, placebo-controlled, multicenter, phase 2 clinical trial in mild to moderate COVID-19 patients. We randomly assigned patients to receive either camostat mesylate (DWJ1248) or placebo orally for 14 days. The primary endpoint was time to clinical improvement of subject symptoms within 14 days, measured using a subjective 4-point Likert scale. Three hundred forty-two patients were randomized. The primary endpoint was nonsignificant, where the median times to clinical improvement were 7 and 8 days in the camostat mesylate group and the placebo group,
References
Beigel, Tomashek, Dodd, Remdesivir for the treatment of COVID-19-preliminary report, Reply. N Engl J Med,
doi:10.1056/NEJMc2022236Chen, Nirula, Heller, Gottlieb, Boscia et al., SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2029849Depfenhart, De Villiers, Lemperle, Meyer, Somma, Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?, Intern Emerg Med,
doi:10.1007/s11739-020-02383-3Gibo, Ito, Kawabe, Hisano, Inoue et al., Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity, Lab Invest,
doi:10.1038/labinvest.3700203Gottlieb, Nirula, Chen, Boscia, Heller et al., Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA,
doi:10.1001/jama.2021.0202Gunst, Staerke, Pahus, Kristensen, Bodilsen et al., Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with COVID-19-a doubleblind randomized controlled trial, EClinicalMedicine,
doi:10.1016/j.eclinm.2021.100849Hoffmann, Hofmann-Winkler, Smith, Krüger, Sørensen et al., Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity, bioRxiv,
doi:10.1101/2020.08.05.237651Hoffmann, Kleine-Weber, Schroeder, Krüger, Herrler et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell,
doi:10.1016/j.cell.2020.02.052Hoffmann, Schroeder, Kleine-Weber, Muller, Drosten et al., Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19, Antimicrob Agents Chemother,
doi:10.1128/AAC.00754-20Horby, Lim, Emberson, Mafham, Bell et al., Dexamethasone in hospitalized patients with COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2021436Iwata-Yoshikawa, Okamura, Shimizu, Hasegawa, Takeda et al., TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection, J Virol,
doi:10.1128/JVI.01815-18Kalil, Patterson, Mehta, Tomashek, Wolfe et al., Baricitinib plus remdesivir for hospitalized adults with COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2031994Keitel, Jensen, Feldt, Fischer, Bode et al., Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial, Trials,
doi:10.1186/s13063-021-05181-0Kim, Cui, Shin, Bae, Kweon et al., Duration of culturable SARS-CoV-2 in hospitalized patients with COVID-19, N Engl J Med,
doi:10.1056/NEJMc2027040Laporte, Naesens, Airway proteases: an emerging drug target for influenza and other respiratory virus infections, Curr Opin Virol,
doi:10.1016/j.coviro.2017.03.018Libster, Marc, Wappner, Coviello, Bianchi et al., Early high-titer plasma therapy to prevent severe COVID-19 in older adults, N Engl J Med,
doi:10.1056/NEJMoa2033700Nicholson, Aoki, Osterhaus, Trottier, Carewicz et al., Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial, Lancet,
doi:10.1016/S0140-6736(00)02288-1Tamura, Hirado, Okamura, Minato, Fujii, Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r-, and C1 esterase, Biochim Biophys Acta,
doi:10.1016/0005-2744(77)90097-3Yamaya, Shimotai, Hatachi, Kalonji, Tando et al., The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells, Pulm Pharmacol Ther,
doi:10.1016/j.pupt.2015.07.001{ 'indexed': {'date-parts': [[2024, 1, 22]], 'date-time': '2024-01-22T22:05:09Z', 'timestamp': 1705961109871},
'reference-count': 22,
'publisher': 'American Society for Microbiology',
'issue': '1',
'license': [ { 'start': { 'date-parts': [[2023, 1, 24]],
'date-time': '2023-01-24T00:00:00Z',
'timestamp': 1674518400000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0/'},
{ 'start': { 'date-parts': [[2023, 1, 24]],
'date-time': '2023-01-24T00:00:00Z',
'timestamp': 1674518400000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://journals.asm.org/non-commercial-tdm-license'}],
'content-domain': {'domain': ['journals.asm.org'], 'crossmark-restriction': True},
'published-print': {'date-parts': [[2023, 1, 24]]},
'abstract': '<jats:p>\n'
' Although several antiviral agents have become available for coronavirus disease '
'2019 (COVID-19) treatment, oral drugs are still limited. Camostat mesylate, an orally '
'bioavailable serine protease inhibitor, has been used to treat chronic pancreatitis in South '
'Korea, and it has an\n'
' <jats:italic>in vitro</jats:italic>\n'
' inhibitory potential against severe acute respiratory syndrome coronavirus 2 '
'(SARS-CoV-2).\n'
' </jats:p>',
'DOI': '10.1128/aac.00452-22',
'type': 'journal-article',
'created': { 'date-parts': [[2022, 12, 14]],
'date-time': '2022-12-14T14:00:56Z',
'timestamp': 1671026456000},
'update-policy': 'http://dx.doi.org/10.1128/asmj-crossmark-policy-page',
'source': 'Crossref',
'is-referenced-by-count': 10,
'title': 'A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy '
'and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19',
'prefix': '10.1128',
'volume': '67',
'author': [ { 'given': 'Yeon-Sook',
'family': 'Kim',
'sequence': 'first',
'affiliation': [ { 'name': 'Department of Internal Medicine, Chungnam National University '
'School of Medicine, Daejeon, South Korea'}]},
{ 'given': 'Seng-Ho',
'family': 'Jeon',
'sequence': 'additional',
'affiliation': [{'name': 'Daewoong Pharmaceutical Co., Ltd., Seoul, South Korea'}]},
{ 'given': 'Junghee',
'family': 'Kim',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Neurosurgery, Seoul Medical Center, Seoul, South '
'Korea'}]},
{ 'given': 'Jong Hoon',
'family': 'Koh',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, Seonam Hospital, Seoul, South '
'Korea'}]},
{ 'given': 'Seung Won',
'family': 'Ra',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, Ulsan University Hospital, '
'University of Ulsan College of Medicine, Ulsan, South Korea'}]},
{ 'given': 'Ji Won',
'family': 'Kim',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, SMG-SNU Boramae Medical Center, '
'Seoul National University College of Medicine, Seoul, South '
'Korea'}]},
{ 'given': 'Yeonjae',
'family': 'Kim',
'sequence': 'additional',
'affiliation': [ { 'name': 'Division of Infectious Diseases, Department of Internal '
'Medicine, National Medical Center, Seoul, South Korea'}]},
{ 'given': 'Choon Kwan',
'family': 'Kim',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, Veterans Health Service Medical '
'Center, Seoul, South Korea'}]},
{ 'given': 'Yun Chul',
'family': 'Shin',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Anesthesiology and Pain Medicine, Gyeonggi '
'Provincial Medical Center Pocheon Hospital, Pocheon, South '
'Korea'}]},
{ 'given': 'Beo Deul',
'family': 'Kang',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, Gyeonggi Provincial Medical '
'Center Ansung Hospital, Ansung, South Korea'}]},
{ 'given': 'Seung ji',
'family': 'Kang',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, Chonmam National University '
'Medical School, Gwangju, South Korea'}]},
{ 'given': 'Chul Hee',
'family': 'Park',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, Gyeonggi Provincial Medical '
'Center Icheon Hospital, Icheon, South Korea'}]},
{ 'given': 'Boyoung',
'family': 'Lee',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, Gyeonggi Provincial Medical '
'Center Uljeongbu Hospital, Uljeongbu, South Korea'}]},
{ 'given': 'Ji Yeon',
'family': 'Lee',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, Keimyung University Dongsan '
'Hospital, Daegu, South Korea'}]},
{ 'given': 'Chung Hoon',
'family': 'Lee',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Obstetrics and Gynecology, Gyeonggi Provincial '
'Medical Center Suwon Hospital, Suwon, South Korea'}]},
{ 'given': 'Jae-phil',
'family': 'Choi',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, Seoul Medical Center, Seoul, '
'South Korea'}]},
{ 'given': 'Jin Yong',
'family': 'Kim',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, Incheon Medical Center, '
'Incheon, South Korea'}]},
{ 'given': 'Shi Nae',
'family': 'Yu',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, Soonchunhyang University '
'Cheonan Hospital, Cheonan, South Korea'}]},
{ 'given': 'Kyong Ran',
'family': 'Peck',
'sequence': 'additional',
'affiliation': [ { 'name': 'Division of Infectious Diseases, Samsung Medical Center, '
'Sungkyunkwan University School of Medicine, Seoul, South '
'Korea'}]},
{ 'given': 'Sung-Han',
'family': 'Kim',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, Asan Medical Center, Seoul, '
'South Korea'}]},
{ 'given': 'Jung Yeon',
'family': 'Heo',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Infectious Diseases, Ajou University School of '
'Medicine, Suwon, South Korea'}]},
{ 'given': 'Hyun ah',
'family': 'Kim',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Medicine, Division of Infectious Diseases, '
'Keimyung University Dongsan Hospital, Keimyung University School '
'of Medicine, Daegu, South Korea'}]},
{ 'given': 'Hyun-jin',
'family': 'Park',
'sequence': 'additional',
'affiliation': [ { 'name': 'Clinical Development Center, Daewoong Pharmaceutical Co., Ltd., '
'Seoul, South Korea'}]},
{ 'given': 'Jongwon',
'family': 'Choi',
'sequence': 'additional',
'affiliation': [ { 'name': 'Clinical Development Center, Daewoong Pharmaceutical Co., Ltd., '
'Seoul, South Korea'}]},
{ 'given': 'Jumi',
'family': 'Han',
'sequence': 'additional',
'affiliation': [ { 'name': 'Clinical Development Center, Daewoong Pharmaceutical Co., Ltd., '
'Seoul, South Korea'}]},
{ 'given': 'JooHyun',
'family': 'Kim',
'sequence': 'additional',
'affiliation': [ { 'name': 'Clinical Development Center, Daewoong Pharmaceutical Co., Ltd., '
'Seoul, South Korea'}]},
{ 'given': 'Hyoung jun',
'family': 'Kim',
'sequence': 'additional',
'affiliation': [ { 'name': 'Clinical Development Center, Daewoong Pharmaceutical Co., Ltd., '
'Seoul, South Korea'}]},
{ 'given': 'Se Hee',
'family': 'Han',
'sequence': 'additional',
'affiliation': [ { 'name': 'Clinical Development Center, Daewoong Pharmaceutical Co., Ltd., '
'Seoul, South Korea'}]},
{ 'given': 'Aeri',
'family': 'Yoon',
'sequence': 'additional',
'affiliation': [ { 'name': 'Clinical Development Center, Daewoong Pharmaceutical Co., Ltd., '
'Seoul, South Korea'}]},
{ 'given': 'MiHee',
'family': 'Park',
'sequence': 'additional',
'affiliation': [ { 'name': 'Clinical Development Center, Daewoong Pharmaceutical Co., Ltd., '
'Seoul, South Korea'}]},
{ 'given': 'SuJung',
'family': 'Park',
'sequence': 'additional',
'affiliation': [ { 'name': 'Clinical Development Center, Daewoong Pharmaceutical Co., Ltd., '
'Seoul, South Korea'}]},
{ 'given': 'YuKyung',
'family': 'Kim',
'sequence': 'additional',
'affiliation': [ { 'name': 'Clinical Development Center, Daewoong Pharmaceutical Co., Ltd., '
'Seoul, South Korea'}]},
{ 'ORCID': 'http://orcid.org/0000-0001-8533-7873',
'authenticated-orcid': True,
'given': 'Minji',
'family': 'Jung',
'sequence': 'additional',
'affiliation': [ { 'name': 'Clinical Development Center, Daewoong Pharmaceutical Co., Ltd., '
'Seoul, South Korea'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-2344-7695',
'authenticated-orcid': False,
'given': 'Myoung-don',
'family': 'Oh',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, Seoul National University '
'College of Medicine, Seoul, South Korea'}]}],
'member': '235',
'reference': [ { 'key': 'e_1_3_4_2_2',
'unstructured': 'World Health Organization. 2022. Weekly epidemiological update on '
'COVID-19. WHO Geneva Switzerland. '
'https://www.who.int/publications/m/item/weekly-epidemiological-update---2-march-2021. '
'Accessed 8 February 2022.'},
{'key': 'e_1_3_4_3_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2021436'},
{'key': 'e_1_3_4_4_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMc2022236'},
{'key': 'e_1_3_4_5_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2031994'},
{'key': 'e_1_3_4_6_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2029849'},
{'key': 'e_1_3_4_7_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2021.0202'},
{'key': 'e_1_3_4_8_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2033700'},
{ 'key': 'e_1_3_4_9_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/0005-2744(77)90097-3'},
{'key': 'e_1_3_4_10_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/labinvest.3700203'},
{'key': 'e_1_3_4_11_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s11739-020-02345-9'},
{ 'key': 'e_1_3_4_12_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.coviro.2017.03.018'},
{'key': 'e_1_3_4_13_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.pupt.2015.07.001'},
{ 'key': 'e_1_3_4_14_2',
'doi-asserted-by': 'crossref',
'unstructured': 'Hoffmann M Hofmann-Winkler H Smith JC Krüger N Sørensen LK Søgaard OS '
'Hasselstrøm JB Winkler M Hempel T Raich L Olsson S Yamazoe T Yamatsuta K '
'Mizuno H Ludwig S Noé F Sheltzer JM Kjolby M Pöhlmann S. 2020. Camostat '
'mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and '
'its metabolite GBPA exerts antiviral activity. bioRxiv. '
'10.1101/2020.08.05.237651.',
'DOI': '10.1101/2020.08.05.237651'},
{'key': 'e_1_3_4_15_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/AAC.00754-20'},
{'key': 'e_1_3_4_16_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/JVI.01815-18'},
{'key': 'e_1_3_4_17_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cell.2020.02.052'},
{'key': 'e_1_3_4_18_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMc2027040'},
{ 'key': 'e_1_3_4_19_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.eclinm.2021.100849'},
{'key': 'e_1_3_4_20_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s13063-021-05181-0'},
{'key': 'e_1_3_4_21_2', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s11739-020-02383-3'},
{ 'key': 'e_1_3_4_22_2',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/S0140-6736(00)02288-1'},
{ 'key': 'e_1_3_4_23_2',
'unstructured': 'National Cancer Institute. 2017. National Cancer Institute Common '
'Terminology Criteria for Adverse Events (CTCAE) v5.0. National Cancer '
'Institute Bethesda MD. '
'https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. '
'Accessed 25 October 2022.'}],
'container-title': 'Antimicrobial Agents and Chemotherapy',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://journals.asm.org/doi/pdf/10.1128/aac.00452-22',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://journals.asm.org/doi/pdf/10.1128/aac.00452-22',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2023, 1, 24]],
'date-time': '2023-01-24T14:02:34Z',
'timestamp': 1674568954000},
'score': 1,
'resource': {'primary': {'URL': 'https://journals.asm.org/doi/10.1128/aac.00452-22'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2023, 1, 24]]},
'references-count': 22,
'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2023, 1, 24]]}},
'alternative-id': ['10.1128/aac.00452-22'],
'URL': 'http://dx.doi.org/10.1128/aac.00452-22',
'relation': {},
'ISSN': ['0066-4804', '1098-6596'],
'subject': [],
'container-title-short': 'Antimicrob Agents Chemother',
'published': {'date-parts': [[2023, 1, 24]]},
'assertion': [ { 'value': '2022-03-28',
'order': 0,
'name': 'received',
'label': 'Received',
'group': {'name': 'publication_history', 'label': 'Publication History'}},
{ 'value': '2022-10-27',
'order': 1,
'name': 'accepted',
'label': 'Accepted',
'group': {'name': 'publication_history', 'label': 'Publication History'}},
{ 'value': '2022-12-14',
'order': 2,
'name': 'published',
'label': 'Published',
'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
